A sensitive procedure for the quantitation of free and N-(2-hydroxypropyl)methacrylamide polymer-bound doxorubicin (PK1) and some of its metabolites, 13-dihydrodoxorubicin, 13-dihydrodoxorubicinone and doxorubicinone, in human plasma and urine by reversed-phase HPLC with fluorimetric detection
Authors:
- E. FrigerioEFE. Frigerio
- E. PianezzolaEPE. Pianezzola
- M. Strolin BenedettiMBM. Strolin Benedetti
- J. CassidyJCJ. Cassidy
- P. VaseyPVP. Vasey
- 1 April 1995
- journal article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 13 (4-5) , 625-633
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Preclinical evaluation of polymer-bound doxorubicinJournal of Controlled Release, 1992
- The pharmacokinetics of polymer-bound adriamycinBiochemical Pharmacology, 1990
- Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 3. Evaluation of adriamycin conjugates against mouse leukaemia L1210 in vivoJournal of Controlled Release, 1989
- Poly(carboxylic acid) polymers as carriers for anthracyclinesJournal of Controlled Release, 1989
- Continuous Infusion or Intravenous Bolus: What Is the Rationale for Doxorubicin Administration?Cancer Drug Delivery, 1987
- Poly-L-aspartic acid as a carrier for doxorubicin: A comparative in vivo study of free and polymer-bound drugBritish Journal of Cancer, 1985
- The synthesis and characterization of polypeptide-adriamycin conjugates and its complexes with adriamycin. Part IJournal of Controlled Release, 1985
- Adriamycin‐loaded albumin microspheres: Preparation, in vivo distribution and release in the ratBiopharmaceutics & Drug Disposition, 1985
- The Anthracycline Antineoplastic DrugsNew England Journal of Medicine, 1981
- Risk Factors for Doxorubicin-lnduced Congestive Heart FailureAnnals of Internal Medicine, 1979